Research Paper Volume 8, Issue 12 pp 3520—3534
Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer
Figure 5C. Immunohistochemical detection of PCNA protein expression (brown color) of saline group, continiuous low-dose doxorubicin group, MSC.sFlt1 group and MSC.sFlt1 plus continuous low-dose doxorubicin group. Combination therapy enhanced the inhibition of tumor cell proliferation in vivo. Magnification, 200×. Data from 3 independent experiments are shown. *p < 0.05, vs MSC.sFlt1 plus continuous low-dose doxorubicin group.